Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624650 | 1.00 | CNR2 (0.69) | CNR2MOGAT2 | |
| SCHEMBL25178052 | 0.89 | CNR2 (0.56) | CNR2 | |
| SCHEMBL31116738 | 0.89 | CNR2 (0.56) | CNR2 | |
| SCHEMBL4472113 | 0.88 | CNR2 (0.65) | CNR2MOGAT2 | |
| SCHEMBL4472316 | 0.85 | CNR2 (0.69) | CNR2MOGAT2 | |
| SCHEMBL13708894 | 0.85 | CNR2 (0.69) | CNR2MOGAT2 | |
| SCHEMBL4467621 | 0.84 | CNR2 (0.67) | CNR2MOGAT2 | |
| SCHEMBL4467627 | 0.84 | CNR2 (0.67) | CNR2MOGAT2 | |
| SCHEMBL9523733 | 0.84 | CNR2 (0.77) | CNR2MOGAT2 | |
| SCHEMBL27405274 | 0.84 | CNR2 (0.77) | CNR2MOGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928103-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-19 | — | — | US | disclosed |
| US-20100029644-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| WO-2008048914-A1 | POLYCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029644-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885MOGAT2 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.